ATXS NASDAQ
Astria Therapeutics, Inc.
1W: +1.5%
1M: +3.7%
3M: +73.6%
1Y: +43.1%
3Y: -11.6%
5Y: -8.3%
$12.58
Last traded 2025-12-31 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$718.1M
52W Range3.555-13.29
Volume3,057,633
Avg Volume1,065,178
Beta0.02
Dividend—
Analyst Ratings
Company Info
CEOJill C. Milne
Employees78
SectorHealthcare
IndustryBiotechnology
IPO Date2015-06-25
Websiteastriatx.com
100 High Street
Boston, MA 02110
US
Boston, MA 02110
US
617 349 1971
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Violin Jonathan | D-Return | 14,100 | $11.35 | 2026-01-23 |
| Violin Jonathan | D-Return | 8,333 | $3.00 | 2026-01-23 |
| Violin Jonathan | D-Return | 14,100 | $9.18 | 2026-01-23 |
| Violin Jonathan | D-Return | 263,321 | — | 2026-01-23 |
| Violin Jonathan | D-Return | 14,166 | $12.24 | 2026-01-23 |